SLC2A9 rs680503: Uric Acid Regulation and Gout Predisposition
The single-nucleotide polymorphism rs680503 is a common genetic variant located in the SLC2A9 gene on chromosome 4. It encodes part of the GLUT9 transporter protein, which plays an essential role in regulating how the kidneys filter and reabsorb uric acid. Population studies have found that variants at this locus are statistically linked to modest shifts in circulating serum urate levels and the corresponding susceptibility to gout.
What each genotype means
Typical urate levels and gout predisposition
You carry two copies of the C allele, which represents the most common genotype globally. In genome-wide association studies, this background is associated with baseline serum urate handling and a typical relative risk for elevated uric acid and gout compared to carriers of the protective T allele. Urate levels are also substantially shaped by diet, kidney function, and other metabolic traits.
Carried by approximately 55% to 60% of individuals worldwide, and roughly 50% of people of European ancestry.
Modestly reduced serum urate
You carry one copy of the T minor allele in SLC2A9. Clinical research associates this allele with slightly enhanced renal urate clearance and moderately lower average circulating uric acid levels, which correlates with a modest reduction in the risk of gout compared to the CC genotype. However, overall gout predisposition continues to depend on lifestyle factors and broader genetic background.
Carried by roughly 35% to 40% of people of European descent and about 30% to 35% of individuals globally.
Reduced serum urate and lower gout risk
You carry two copies of the T allele, which research associates with the strongest protective effect at this locus against elevated serum urate concentrations and gout. Individuals with this genotype generally exhibit lower average uric acid levels due to altered transporter dynamics in the kidneys. These findings reflect statistical population trends and do not preclude hyperuricemia if other genetic or environmental risk factors are present.
Carried by approximately 4% to 8% of people of European ancestry and fewer than 5% of individuals in most other global populations.
Genomic Location and Variant Characteristics
The rs680503 polymorphism is situated on chromosome 4 within the SLC2A9 gene (solute carrier family 2 member 9). This locus features a single-nucleotide substitution where an adenine (A) allele alternates with a guanine (G) allele. Because the SLC2A9 locus harbors multiple functional coding and non-coding alterations, rs680503 has been studied both directly and as part of broader haplotype blocks in link with urate clearance. Variations across this region directly influence how transporter genes maintain metabolic homeostasis in the human body.
Biological Role of SLC2A9 and GLUT9
The SLC2A9 gene encodes glucose transporter 9 (GLUT9), a facilitative hexose and organic anion transporter prominently expressed in the proximal tubules of the human kidneys and in liver hepatocytes. While originally categorized as a fructose transporter, extensive cellular and molecular assays have demonstrated that GLUT9 acts as a high-capacity transporter for urate. By mediating the reabsorption and secretion of uric acid across renal epithelial membranes into the bloodstream, GLUT9 serves as one of the primary physiological determinants of circulating serum urate levels in humans.
Health Associations and Evidence Strength
Genome-wide association studies (GWAS) and candidate gene analyses consistently identify SLC2A9 as one of the strongest genetic determinants of serum uric acid levels and primary gout. However, specific individual non-synonymous or intronic tagging SNPs, including rs680503, possess limited standalone predictive strength. Rather than causing monogenic disease, these variants typically exert subtle additive effects on uric acid concentration, often explaining a small fraction of population-wide phenotypic variance. The clinical impact of these alleles can also vary by biological sex, with several cohorts demonstrating pronounced effects in females due to hormonal modulation of transporter activity.
Ancestry and Population Patterns
Allele frequencies for SLC2A9 variants, including rs680503, display marked geographic and ancestral differences across worldwide populations. The minor allele frequency is estimated at approximately 0.24 globally, reaching substantially higher frequencies in individuals of European ancestry compared to some East Asian or African lineages. Because linkage disequilibrium architecture differs among demographic groups, the predictive value of specific single-nucleotide variants may not generalize uniformly across all ancestries, underscoring the importance of multi-ethnic genetic research.
Clinical Utility and Lifestyle Context
Carrying an allele associated with altered urate clearance does not constitute a clinical diagnosis of hyperuricemia or gout, nor does a protective genotype guarantee immunity against joint inflammation. Uric acid levels are strongly shaped by modifiable environmental factors, including dietary purine intake, alcohol consumption, metabolic health, renal function, and medication use such as diuretics. Genetic data from rs680503 provide informational context about baseline physiological tendencies. Any clinical decisions regarding urate-lowering therapy or dietary modifications should always be directed by formal laboratory testing and consultation with a healthcare provider.
How common is this variant?
The minor allele exhibits a frequency of approximately 0.24 globally, occurring with higher prevalence in European ancestry cohorts compared to African and East Asian populations.
Frequently asked questions
What is the primary function of the SLC2A9 gene?
The SLC2A9 gene provides instructions for creating GLUT9, a specialized transport protein located primarily in the kidneys. GLUT9 facilitates the transport of uric acid out of renal tubules and back into circulation, directly helping govern uric acid balance.
Does having a risk genotype at rs680503 mean I will develop gout?
No. Genotypes at rs680503 confer only a modest statistical predisposition and are not diagnostic. The development of hyperuricemia and gout depends on a combination of broader polygenic factors, diet, alcohol intake, kidney health, and lifestyle.
Can diet overcome a genetic predisposition to high uric acid?
Yes, lifestyle and dietary modifications play a significant role in managing urate levels. Maintaining healthy hydration, limiting alcohol and sugar-sweetened beverages, and moderating foods high in purines can help manage uric acid concentrations regardless of genotype.
Should I adjust any medications based on my rs680503 result?
No. Genetic test results for rs680503 should never be used to initiate, stop, or change medication dosages. Any pharmacological management of hyperuricemia or gout should be evaluated and managed directly by a qualified clinician.
Sources & further reading
Educational information only, last refreshed 9/13/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs680503?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in SLC2A9
Functional variant in SLC2A9 significantly associated with serum uric acid levels and susceptibility to gout.
This SNP is linked to variations in serum uric acid levels and the risk of developing gout.
Increases the risk of high uric acid levels and gout.